Ahead of the Autumn Statement, the ABPI alongside 10 other partners from across the life sciences sector, has called upon the Chancellor to use the Autumn Statement an opportunity to send a strong message that the UK is open for business and remains a premier destination to work on health research that improves lives.
Health research is one of the UK’s great strengths driven by talented people, world-class universities, a thriving life sciences industry, patient-centred medical research charities and the unrivalled research potential of the NHS.
The open letter calls on the Chancellor to recommit to making the UK a global hub for life sciences as set out in the 2019 Conservative Manifesto and maintaining the 2021 Spending Review commitment to invest £20billion per year by 2024/25 and £22billion by 2026/27 in public R&D.
• Ensuring health research investment is balanced across Government research funders and maintaining previously set out commitments for both UK Research and Innovation (UKRI) and the National Institute for Health and Care Research (NIHR).
• Reaffirming that funding set aside for association to Horizon Europe will be spent on research and innovation whether or not we are able to associate.
• Supporting public investment with internationally competitive R&D tax incentives that will leverage further private investment from innovative and research-intensive life sciences companies.
- Clinical research
Last modified: 20 September 2023
Last reviewed: 20 September 2023